Angiogenesis inhibitors

Angiogenesis inhibitors. These are a class of pharmaceutical agents designed to halt the formation of new blood vessels, a process known as Angiogenesis. By targeting specific signaling pathways and growth factors, these drugs aim to starve tumors of the oxygen and nutrients they need to grow and metastasize. Their development represents a pivotal shift in therapeutic strategies, moving beyond traditional cytotoxic chemotherapy to more targeted approaches. The clinical utility of these agents extends beyond Oncology into ocular diseases and other conditions characterized by pathological vascular proliferation.

Mechanism of action

The primary mechanism involves the blockade of pro-angiogenic factors, most notably Vascular endothelial growth factor and its corresponding receptors. Agents like Bevacizumab function as monoclonal antibodies that bind directly to circulating VEGF, preventing its interaction with endothelial cell receptors. Small molecule inhibitors such as Sunitinib and Sorafenib target intracellular tyrosine kinase domains of receptors for VEGF, Platelet-derived growth factor, and other factors. This inhibition disrupts critical downstream signaling cascades, including the MAPK/ERK pathway and PI3K/AKT/mTOR pathway, leading to endothelial cell apoptosis and regression of immature tumor vasculature. Other strategies involve targeting alternative pathways like the Angiopoietin-TIE axis or inhibiting matrix metalloproteinases to prevent vascular remodeling.

Clinical applications

The foremost application is in the treatment of various malignancies. They are standard-of-care for metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma, often in combination with cytotoxic regimens. In Ophthalmology, agents like Aflibercept and Ranibizumab are intravitreally administered to manage neovascular Age-related macular degeneration, diabetic macular edema, and retinal vein occlusion by inhibiting ocular angiogenesis. Research explores their use in other angiogenesis-dependent conditions such as endometriotic lesions, psoriatic plaques, and arteriovenous malformations.

Approved drugs

Numerous agents have received approval from regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency. Major monoclonal antibody inhibitors include Bevacizumab and Ramucirumab. Fusion proteins like Aflibercept act as soluble decoy receptors. A broad range of oral tyrosine kinase inhibitors are approved, including Sunitinib, Sorafenib, Pazopanib, Axitinib, Cabozantinib, and Lenvatinib. Specific inhibitors for ocular use include Ranibizumab and Brolucizumab. The National Comprehensive Cancer Network guidelines incorporate many of these drugs into treatment algorithms for cancers such as those treated at the Memorial Sloan Kettering Cancer Center and the MD Anderson Cancer Center.

Adverse effects

The systemic inhibition of physiological angiogenesis leads to a characteristic toxicity profile. Common class-effects include drug-induced hypertension, renal proteinuria, and impaired surgical wound healing. Bleeding events and arterial thromboembolic events like myocardial infarction are significant risks. Gastrointestinal effects such as diarrhea, hand-foot skin reaction, and thyroid dysfunction are frequent with kinase inhibitors. Ocular agents can cause intraocular inflammation, retinal detachment, and increased intraocular pressure. These toxicities are monitored in clinical trials overseen by entities like the National Cancer Institute.

Research and development

Ongoing research focuses on overcoming mechanisms of resistance, such as upregulation of alternative pro-angiogenic factors like Fibroblast growth factor and Placental growth factor. Strategies include developing multi-targeted agents and rational combination therapies with immune checkpoint inhibitors like Pembrolizumab or Atezolizumab. Nanoparticle-based delivery systems aim to improve tumor specificity and reduce systemic exposure. Investigations into predictive biomarkers for patient selection are critical, driven by consortia like the Cancer Genome Atlas. Furthermore, research extends to non-oncologic fields, exploring efficacy in rheumatoid arthritis and atherosclerotic plaque stabilization, as presented in forums like the American Association for Cancer Research annual meeting.

Category:Antineoplastic drugs Category:Angiogenesis